Atlas Trials

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Clinical trial NCT02362035 · COMPLETED

Trial details

NCT number
NCT02362035
Sponsor
Acerta Pharma BV
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Follicular Lymphoma (FL)CLLSmall Lymphocytic Lymphoma (SLL)Richter's SyndromeMantle Cell Lymphoma (MCL)Indolent Non Hodgkin LymphomaWaldenström MacroglobulinemiaMultiple MyelomaHodgkin LymphomaBurkitt LymphomaMarginal Zone LymphomasMediastinal Large B Cell Lymphoma
Start date
2015-02-20
Primary completion
2020-07-14
Enrollment
161

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.